- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06854419
Efficacy Evaluation of Blood Peach Extract and Rose Apple Extract on Skin
July 28, 2025 updated by: TCI Co., Ltd.
Evaluate the effects of blood peach extract drink and rose apple extract drink on enhancing hemoglobin and iron levels, and improving skin health.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung City, Taiwan, 406040
- China Medical University of Department of Cosmeceutics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy adult females aged 20 to 65;
- Preferably those with pale complexion or signs of iron deficiency anemia.
Exclusion Criteria:
- Currently undergoing or having undergone any medical beauty treatments within the past month (including skincare, laser treatments, chemical peel, injections, or cosmetic surgery);
- Outdoor workers (exposed to sunlight for more than 5 hours daily);
- Pregnant, breastfeeding, or planning to become pregnant during the trial (self-reported);
- Individuals with heart, liver, kidney, endocrine, or other significant organic diseases (self-reported);
- Individuals who have undergone major surgery (according to medical history);
- Long-term medication users;
- Individuals with mental health disorders;
- Those who are already regularly taking iron supplements;
- Faculty or staff members who are currently enrolled in the principal investigator's courses.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Take one bottle of the product every morning on an empty stomach
|
|
Experimental: Blood Peach Extract
|
Take one bottle of the product every morning on an empty stomach
|
|
Experimental: Rose Apple Extract
|
Take one bottle of the product every morning on an empty stomach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the volume of skin wrinkles
Time Frame: Volume change from Baseline skin wrinkles at 8 weeks
|
IRV full-face skin analyzer was utilized to measure skin wrinkles.
Units: arbitrary units
|
Volume change from Baseline skin wrinkles at 8 weeks
|
|
the roughness of skin texture
Time Frame: Rating skin roughness from Baseline skin texture at 8 weeks
|
IRV full-face skin analyzer was utilized to measure skin texture.
Units: arbitrary units
|
Rating skin roughness from Baseline skin texture at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the change of skin elasticity
Time Frame: Change from Baseline skin elasticity at 8 weeks
|
Cutometer® was utilized to measure skin elasticity.
Units: arbitrary units
|
Change from Baseline skin elasticity at 8 weeks
|
|
the change of skin collagen density
Time Frame: Change from Baseline skin collagen density at 8 weeks
|
Dermalab® Combo was utilized to measure skin collagen density.
Units: arbitrary units
|
Change from Baseline skin collagen density at 8 weeks
|
|
the change of skin pores
Time Frame: Change from Baseline skin pores at 8 weeks
|
IRV full-face skin analyzer was utilized to measure skin pores.
Units: arbitrary units
|
Change from Baseline skin pores at 8 weeks
|
|
the change of skin tone
Time Frame: Change from Baseline skin tone at 8 weeks
|
IRV full-face skin analyzer was utilized to measure skin tone.
Units: arbitrary units
|
Change from Baseline skin tone at 8 weeks
|
|
the change of skin hydration
Time Frame: Change from Baseline skin hydration at 8 weeks
|
Corneometer® was utilized to measure skin hydration.
Units: arbitrary units
|
Change from Baseline skin hydration at 8 weeks
|
|
the change of skin melanin/erythema index
Time Frame: Change from Baseline skin melanin/erythema index at 8 weeks
|
Mexameter® was utilized to measure skin melanin/erythema index.
Units: arbitrary units
|
Change from Baseline skin melanin/erythema index at 8 weeks
|
|
the change of skin redness
Time Frame: Change from Baseline skin redness at 8 weeks
|
Colorimeter was utilized to measure skin redness.
Units: arbitrary units
|
Change from Baseline skin redness at 8 weeks
|
|
the change of lip redness
Time Frame: Change from Baseline lip redness at 8 weeks
|
Antera 3D® was utilized to measure lip redness.
Units: arbitrary units
|
Change from Baseline lip redness at 8 weeks
|
|
the change of Red Blood Cells (RBC) Count of blood
Time Frame: Change from Baseline RBC count at 8 weeks
|
venous blood was sampled to measure RBC count
|
Change from Baseline RBC count at 8 weeks
|
|
the change of hemoglobin level of blood
Time Frame: Change from Baseline hemoglobin level at 8 weeks
|
venous blood was sampled to measure hemoglobin level
|
Change from Baseline hemoglobin level at 8 weeks
|
|
the change of mean corpuscular volume (M.C.V) level of blood
Time Frame: Change from Baseline M.C.V level at 8 weeks
|
venous blood was sampled to measure M.C.V level
|
Change from Baseline M.C.V level at 8 weeks
|
|
the change of mean corpuscular hemoglobin concentration (M.C.H.C) level of blood
Time Frame: Change from Baseline M.C.H.C level at 8 weeks
|
venous blood was sampled to measure M.C.H.C level
|
Change from Baseline M.C.H.C level at 8 weeks
|
|
the change of ferrous level of blood
Time Frame: Change from Baseline ferrous level at 8 weeks
|
venous blood was sampled to measure ferrous level
|
Change from Baseline ferrous level at 8 weeks
|
|
the change of ferritin level of blood
Time Frame: Change from Baseline ferritin level at 8 weeks
|
venous blood was sampled to measure ferritin level
|
Change from Baseline ferritin level at 8 weeks
|
|
the change of Total Iron Binding Capacity (TIBC) level of blood
Time Frame: Change from Baseline TIBC level at 8 weeks
|
venous blood was sampled to measure TIBC level
|
Change from Baseline TIBC level at 8 weeks
|
|
the change of unsaturated iron-binding capacity (UIBC) level of blood
Time Frame: Change from Baseline UIBC level at 8 weeks
|
venous blood was sampled to measure UIBC level
|
Change from Baseline UIBC level at 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the change of liver function biomarkers (AST, ALT) of blood
Time Frame: change from Baseline liver function biomarkers at 8 weeks
|
venous blood was sampled to measure liver function biomarkers
|
change from Baseline liver function biomarkers at 8 weeks
|
|
the change of renal function biomarkers (creatinine, BUN) of blood
Time Frame: change from Baseline renal function biomarkers at 8 weeks
|
venous blood was sampled to measure renal function biomarkers
|
change from Baseline renal function biomarkers at 8 weeks
|
|
the change of fasting glucose level of blood
Time Frame: change from Baseline fasting glucose level at 8 weeks
|
venous blood was sampled to measure fasting glucose level
|
change from Baseline fasting glucose level at 8 weeks
|
|
the change of Advanced glycation end products (AGEs) level of blood
Time Frame: change from Baseline AGEs level at 8 weeks
|
venous blood was sampled to measure AGEs level
|
change from Baseline AGEs level at 8 weeks
|
|
The change of self-assessment skin and metabolic circulation condition
Time Frame: Change from Baseline skin and metabolic circulation condition at 8 weeks
|
A self-assessment questionnaire was collected to evaluate skin and metabolic circulation condition.
As for the evalutation of skin condition, the higher score the better; As for evaluation of metabolic circulation condition, the higher score the worse.
|
Change from Baseline skin and metabolic circulation condition at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hsiu-Mei Chiang, China Medical University of Department of Cosmeceutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 7, 2025
Primary Completion (Actual)
June 30, 2025
Study Completion (Actual)
July 15, 2025
Study Registration Dates
First Submitted
February 25, 2025
First Submitted That Met QC Criteria
February 25, 2025
First Posted (Actual)
March 3, 2025
Study Record Updates
Last Update Posted (Actual)
July 30, 2025
Last Update Submitted That Met QC Criteria
July 28, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CMUH114-REC3-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatology
-
Syneron MedicalCompletedAesthetic DermatologyUnited States
-
Northwestern UniversityCompleted
-
Northwestern UniversityCompleted
-
Kylane LaboratoiresEurofins Dermscan PharmascanCompletedAesthetic DermatologySwitzerland
-
BelleTorus CorporationUrban Health Plan Inc.RecruitingSkin Condition | Dermatology/Skin - Other | DermatologyUnited States
-
Northwestern UniversityCompletedDermatology/Skin - OtherUnited States
-
Joanneum Research Forschungsgesellschaft mbHCompletedDermal Pharmacokinetic Measurements | Dermatology/Skin - OtherAustria
-
Habelo BeautyCitruslabsCompletedSkin Care | Skin Health | DermatologyUnited States
-
University Hospitals Coventry and Warwickshire...University Hospital, GenevaTerminatedTopical Corticosteroid-treated Dermatology Patients | Intra-ocular PressureUnited Kingdom
Clinical Trials on Placebo Drink
-
Wageningen UniversityMaastricht University Medical Center; Top Institute Food and NutritionCompleted
-
Mayo ClinicCompletedCardiovascular System | Hemodynamics | Energy DrinksUnited States
-
Virginia Polytechnic Institute and State UniversityCompletedCardiovascular Risk FactorUnited States
-
University of California, RiversideA1CantusNot yet recruiting
-
University of the PacificCompletedCardiovascular DiseasesUnited States
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedMuscle Loss in ElderlyNetherlands
-
University of LimerickCompleted
-
TCI Co., Ltd.Completed